Fiche publication
Date publication
janvier 2021
Journal
Atherosclerosis
Auteurs
Membres identifiés du Cancéropôle Est :
Dr LAGROST Laurent
,
Pr MASSON David
,
Dr AIRES Virginie
,
Mme BATAILLE Amandine
Tous les auteurs :
Gautier T, Deckert V, Aires V, Le Guern N, Proukhnitzky L, Patoli D, Lemaire S, Maquart G, Bataille A, Xolin M, Magnani C, Masson D, Harscoët E, Da Silva B, Houdebine LM, Jolivet G, Lagrost L
Lien Pubmed
Résumé
Apolipoprotein (apo) C1 is a 6.6 kDa protein associated with HDL and VLDL. ApoC1 alters triglyceride clearance, and it also favors cholesterol accumulation in HDL, especially by inhibiting CETP in human plasma. Apart from studies in mice, which lack CETP, the impact of apoC1 on atherosclerosis in animal models expressing CETP, like in humans, is not known. This study aimed at determining the net effect of human apoC1 on atherosclerosis in rabbits, a species with naturally high CETP activity but with endogenous apoC1 without CETP inhibitory potential.
Mots clés
Apolipoprotein C1, Atherosclerosis, CETP, HDL, Rabbit, Transgenic
Référence
Atherosclerosis. 2021 Jan 12;320:10-18
